China gives conditional approval for Pfizer’s Paxlovid, country’s first oral anti-Covid pill
It can be given to patients with diabetes, and chronic renal and cardiovascular diseases
Your support helps us to tell the story
From reproductive rights to climate change to Big Tech, The Independent is on the ground when the story is developing. Whether it's investigating the financials of Elon Musk's pro-Trump PAC or producing our latest documentary, 'The A Word', which shines a light on the American women fighting for reproductive rights, we know how important it is to parse out the facts from the messaging.
At such a critical moment in US history, we need reporters on the ground. Your donation allows us to keep sending journalists to speak to both sides of the story.
The Independent is trusted by Americans across the entire political spectrum. And unlike many other quality news outlets, we choose not to lock Americans out of our reporting and analysis with paywalls. We believe quality journalism should be available to everyone, paid for by those who can afford it.
Your support makes all the difference.China on Friday granted conditional approval for Pfizer’s Paxlovid, the first Covid-19 oral pill cleared in the country for adults with mild to moderate symptoms and at a higher risk of becoming more seriously ill, according to reports.
The small-molecule oral drug is a co-package of nirmatrelvir and ritonavir drugs, according to the National Medical Products Administration (NMPA), news agency Xinhua reported.
It can be given to patients with chronic renal diseases, diabetes, cardiovascular diseases, and chronic lung diseases, the Chinese drugs regulator said.
Further study on the drug needed to be conducted and submitted to the authority, NMPA said.
“This is an important milestone in our fight against COVID-19,” Reuters quoted a Pfizer representative as saying.
Pfizer executives have said the company is in active discussions with over 100 countries about Paxlovid and has the capacity to provide 120 million courses if needed.
Pfizer in December said final trial results showed its treatment reduced the chance of hospitalisation or death by 89% in COVID-19 patients at risk of severe illness given the treatment within three days of the onset of symptoms, and by 88% when given within five days of onset.
The US is paying around $530 for each course of Paxlovid and $700 for each course of rival COVID-19 pill molnupiravir developed by Merck & Co.
There have been 106,764 infections and 4,636 coronavirus-related deaths reported in China since the pandemic began, according to a Reuters graphic.
(with inputs from agencies)
Join our commenting forum
Join thought-provoking conversations, follow other Independent readers and see their replies
Comments